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Twelve mongrel dogs were randomly allocated into two groups using matched paired-design. Catheters
were inserted into the hepatic artery, hepatic vein and the femoral vein, respectively. In the first group,
gelfoam supplemented with mitomycin C (MMC) was injected into the hepatic artery, whereas the
second group received a hepatic arterial injection of MMC solution alone. Simultaneous blood sampling
from the hepatic and femoral veins at regular intervals was performed. MMC concentrations in plasma
was determined using high performance liquid chromatography (HPLC) and the pharmacokinetics of
MMC were determined.
MMC concentrations in hepatic and femoral veins did not differ and no significant difference in
pharmacokinetics was found when comparing MMC administration into the hepatic artery with or
without gelfoam supplementation. Thus, our results revealed that gelfoam could not delay the clearance
of MMC from the liver.
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INTRODUCTION
Mitomycin C (MMC) is an antitumor drug with supposed broad spectrum of
antitumor activity, first isolated from Streptomyces caespitosus by Wakaki et al. in
1958. The previously used low-dose regimen caused severe myelosuppression,
resulting in only limited use of the drug in the last 20 years. The myelosuppressive
adverse effect diminished to a great extent by using a high-dose intermittent
schedule2. Following advances in understanding of the blood supply of hepatic
tumors it was found that liver cancer derives its blood supply almost exclusively
from the hepatic artery3. This fact focused attention on local treatment of hepatic
tumors through the hepatic artery. By selectively increasing the concentrations in
tumor tissue, adverse effects on normal cells could be diminished, reducing
systemic toxicity and at the same time compensating the low therapeutic index of
MMC. This goal could be achieved by bolus intraarterial chemotherapy. MMC,
however, proved to present a transient high level in the target tissue, after which it
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was rapidly cleared from the tissue5’6. Chemoembolization, including both infarc-
tion and prolonged drug action7, was thought to postpone the tissue clearance.
Hepatic arterial chemoembolization (HACE) by gelfoam supplemented with MMC
has been used for unresectable liver cancer8-1. The advantages of this mode of
treatment is that gelfoam embolization can induce ischemia or even necrosis of
tumor tissue and creates an anaerobic environment increasing the effect of
MMC11’2. Moreover, MMC was supposed to be released slowly, thereby reducing
the systemic toxicity of MMC. Only limited data on the pharmacokinetics of MMC
have, however, been presented due to the lack of sensitive and selective detecting
methods. In 1979, Kono et al. 3 reported on the use of high performance liquid
chromatography (HPLC) for determination of MMC in biological samples.
The purpose of the present study was to compare the pharmacokinetics of MMC
after HACE (hepatic arterial chemoembolization using gelfoam and MMC) as
compared to hepatic arterial "one-shot" (HAOS), i.e. a bolus injection of MMC
alone.
MATERIALS AND METHODS
Twelve mongrel dogs weighing 12-16 Kg were used for the experiments, randomly
allocated into two groups: hepatic arterial "one shot" (HAOS), i.e. a bolus
injection of MMC alone, and hepatic arterial chemoembolization (HACE), i.e.
MMC and gelfoam together, using matched-paired design. Student’s t test was used
for statistical analysis. Statistical significance was defined as probability level
p<0.05.
Preparations
All chemicals used in the experiments were of analytical grade and used without
further purification. The pure mitomycin C was purchased from Kyowa
Hakkokogyo (Tokyo, Japan).
Gelfoam, 24 cm (Wuhan biochemical Co., China), average weight 320 mg, was
cut into small pieces of about 1 1 mm in size using the method described by Bank
et al. TM, after which the small pieces were sterilized with steam.
MMC, 1 mg/Kg body weight, was dissolved in 20 ml of normal saline and drawn
into a glass syringe with gelfoam particles.
Experimental Protocol
Two catheters (I.D. 1.47 mm, O.D. 1.96 mm, dow Corning, Michigan, USA) were
inserted into the femoral vein and left or right hepatic artery through the
gastroduodenal artery, respectively, under phenobarbital anaesthesia (30 mg/Kg
body weight). Methylene blue was injected in the hepatic artery, after which the
extent and degree of the blue staining on the surface of the liver was observed. A
cardiac catheter (8-F, Shanghai Medical Instrument Co., China) was introduced
into the corresponding hepatic vein of the blue stained lobe about 3-4 cm via the
jugular vein. An intrahepatic, cord-like mass was then palpable on the surface of
the liver, moving when the catheter was partly pulled out, confirming the catheter
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position in the hepatic vein. Further verification of the position was obtained at
autopsy.
MMC or the mixthre of gelfoam and MMC was injected into the left or right
hepatic artery after catheterization. The syringe was rotated continually during the
slow injection (1-2 min.).
Blood Sampling
Blood (1 ml) was simultaneously sampled from the indwelling catheters in the
hepatic and femoral veins into heparinized glass tubes prior to injection and at 0, 2,
5, 10, 15, 30, 60, 120, 180, 240, 300 and 360 minutes after injection. The blood
samples were centrifuged at 3,000 rpm for 5 minutes, after which red blood cells
and plasma were separated and plasma samples frozen at -30 C until analysis.
HPLC Assay
A modification of den Hartigh’s method!5 for plasma MMC extraction and
detection was used. 0.5 ml plasma was mixed twice with 5 ml of chloroform/
isopropanol (1:1, w/w), shaken for two minutes, and centrifuged at 3,000 rpm for 5
minutes. The organic supernant was transferred into conical glass tubes and
evaporated to dryness under nitrogen stream in 40 C water bath. The residue was
dissolved in 100/1 methanol. A 20/1 aliquot was used for the liquid chromatogra-
phy analysis.
The high performance liquid chromatography system consisted of a LC-3 solvent
delivery system, SPD-1 ultraviolet detector, CR-1B data processor (all from
Shimadzu Co., Japan), YQG-5 C18 4.6 200 mm reverse phase column (Dalian
Chromatography Technique Exploiting Co., China). The mobile phase (60% water
and 40% methanol) was pumped at 0.8 ml/min. The detector was operated at 365
nm and the retention time was approximately 7 minutes. The standard curve for the
drug dissolved in methanol was linear from 5 to 500 ng/ml. The recovery of MMC in
plasma was 81 + 5.2%, and the limit of determination was 50 ng/ml plasma.
Pharmacokinetic Data Analysis
The data on MMC concentrations in plasma was put into an IBM-PC computer
operated with a PKBP-N1 pharmacokinetic analysis program package (Dept. of
Computer, Army General Hospital of Nanjin Area, China) and depicting the real
MMC concentration versus time on a semilogarithmic curve. The curve had a
typically biphasic distribution compatible with a two compartment open model.
Each set of experimental data fitted to a biexponential equation, C Ae-at + Be-t,
and the pharmacokinetic parameters were calculated from computer-generated
coefficients and exponents as described by Wagner16. Finally, the theoretical
concentration versus the time curve, simulated by the computer, was drawn.
RESULTS
The theoretical curve simulated by the computer, was very close to the real
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concentration values. The regression coefficients were 0.9-0.99. No statistically
significant differences (p >0.05) in MMC pharmacokinetics calculated by MMC
concentrations in the hepatic and femoral veins were found neither between the
two groups (Table 1, 2) nor within the same group.
Table MMC pharmacokinetic parameters in HACE group (mean + SEM)
Route T1/2a T1/2 Vc Vd CI AUC
Hepatic vein 4.41+0.77 91.63+5.59 0.562+0.056 2.277+0.289 17.991+2.990 65.05+13.22
Femoral vein 5.70+ 1.29 75.57+7.81 0.831+0.127 1.944+0.309 17.849+2.049 61.30+9.57
T/2 (min) Half-time of distribution phase
TI/2//(min) Half-time of elimination phase
Vc (L/Kg) Central compartment volume of distribution
Vd (L/kg) Apparent volume distribution
CI (ml/min/Kg) Total body clearance
AUC (ml/min/kg)Area under the curve
Table 2 MMC pharmacokinetic parameters in HAOS group (mean + SEM)
Route Tv2a T1/2 Vc Vd Cl AUC
Hepatic vein 4.16+0.58 86.02+4.29 0.339+0.0p78 1.591+0.171 13.122+1.528 83.19+11.14
Femoralvein 5.29+0.37 54.91+5.81 0.680+0.137 1.688+0.382 21.009+4.417 57.53+10.13
T/2. (min) Half-time of distribution phase
TI/2t (min) Half-time of elimination phase
Vc (L/Kg) Central compartment volume of distribution
Vd (L/kg) Apparent volume distribution
CI (ml/min/Kg) Total body clearance
AUC (ml/min/kg)Area under the curve
DISCUSSION
The pharmacokinetic behavior of MMC administered through a peripheral vein has
been studied by several authors17-21. Some18-22 have also investigated the pharma-
cokinetics of MMC administered in combination with other antineoplastic agents.
van Hazel et al.2 reported that other antineoplasti’c agents did not apparently affect
the pharmacokinetic course of MMC, while Verweij et al. 9 found that total body
clearance of MMC was obviously increased, whereas the area under the curve
(AUC) remarkably decreased when MMC was used in combination with other
antitumor agents. The reported pharmacokinetics of MMC are somewhat contro-
versial. According to the results of den Hartigh7, pharmacokinetics of MMC
appeared to be non-linear, dose-dependent, van Hazel et al.2 and Schilcher et al. 21,
however, showed that the pharmacokinetics of MMC administered in different
doses up to 60 mg/m was not dose-dependent. Hu et al. 25 and Gyves et al. 26 studied
the pharmacokinetics of MMC infused into the hepatic artery, and the local
concentration of MMC was found to be 3--4 times higher than that following
infusion through a peripheral vein. Systemic toxicity was, however, not reduced by
hepatic artery infusion.
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MMC has been reported to be eliminated through the kidney, liver, and bile.
MMC is eliminated through the kidney by glomerular filtration independent of
renal function2’27’28. The concentration of MMC in bile was found to be several
times higher than in plasma23, and the elimination of MMC was not influenced even
by cholestasis28’29. Enzymatic inactivation of MMC was potent especially under
anaerobic conditions3. Currently, the exact clearance mechanisms of MMC are not
clear, but van Hazel et al. 29 have stressed the influence of liver function on the
elimination of MMC, and the liver has been regarded as a major route of clearance
of MMC22.
In the present study, no statistical difference in elimination could be seen, as
calculated by MMC plasma concentrations in the hepatic and femoral veins, even
though the half-time tended to be longer in the group with MMC and gelfoam
(HACE) as compared to MMC alone (HAOS) infused into the hepatic artery. This
indicates that the addition of gelfoam to MMC could not retard the elimination of
MMC from the liver. Both in the HACE group and in the HAOS group, the values
of the central compartment volume of distribution was about half of the apparent
volume of distribution. The distribution of MMC in the circulation and in the
systemic tissue was thus equal, and there was no apparent MMC accumulation in
tissue. These results are consistent with those of Malviya et al. 32. The difference in
the area under the concentration-time curve of MMC in the femoral vein between
the two groups was not statistically significant, demonstrating that systemic expo-
sure and toxicity of MMC following both therapies should be the same. Also the
concentration-time curves of MMC in the hepatic vein was similar in the two
groups, further confirming that the release of MMC in the hepatic vein was the
same, supporting the findings of Kato et al. 33.
The similar pharmacokinetics of MMC following both therapies might be
explained by the following mechanisms. As gelfoam particles only occupied a small
part of the 20 ml of MMC solution, a large proportion of the drug could be
expected to be in a free state. Also the arterial pressure distal to the embolized
arteries reduces, thereby increasing the pressure gradient to the systemic circula-
tion after hepatic arterial embolization, inducing opening of pre-existing collaterals
and arterioportal shunts34-37. Non-encapsulated MMC might also be metabolized
by liver enzymes.
In conclusion, our results show that the pharmacokinetic behavior of MMC was
similar both following hepatic arterial chemoembolization using MMC and gelfoam
and hepatic arterial injection of MMC alone. This implies that mechanical emboli-
zation using gelfoam is not sufficient to prolong MMC clearance from liver tissue.
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INVITED COMMENTARY
It is more than two decades since hepatic artery infusion chemotherapy for tumors
of the liver was first used in clinical cases. That therapy was demonstrated to
achieve a high drug concentration in the tumor tissue, and it was anticipated that
the therapy would enable reduction of systemic adverse reactions. Therefore, the
technique was aggressively applied to clinical cases, and good antitumor efficacy
has been reported. In the 1970’s, transarterial embolization (TAE) with Gelfoam
was devised for hepatocellular carcinoma, and a survival rate almost equal to that
with surgery was reported, especially in patients with unresectable hepatoma. The
effect of TAE was surmised to be derived from its embolization of tumor vessels
and subsequent ischemic necrosis of the tumor. However, only a few reports have
dealt with the pharmacokinetics of infused anti-tumor agents, including whether or
not washout of the drugs is delayed by the decreased blood flow. Dr. Ding studied
the pharmacokinetics of MMC after chemoembolization with Gelfoam and con-
cluded that mechanical embolization using Gelfoam is not sufficient to significantly
delay MMC clearance from the liver tissue.
However, if we assumed that Gelfoam can retain MMC in it and release of MMC
into the blood is prolonged, the pharmacokinetics of MMC in chemoembolization
should fit the two-compartment model with a first-order absorption process (C
-He-kat d- Aeat + Be-t), because transition of MMC from Gelfoam into the blood
flow can be simulated to the absorption process from muscle or the intestine. The
apparent release of MMC from Gelfoam suspension is actually very fast; that is, the
value of ka is very large, and -He-kat can be considered negligible. Therefore, the
pharmacokinetics of MMC can be considered to approximate a biexponential
equation. The fact that the curve of the real MMC concentration versus time is
close to the theoretical biphasic curve implies that the Gelfoam suspension has no
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delayed-release effect on MMC. Moreover, the absence of a significant difference
in the pharmacokinetics of MMC with or without Gelfoam supplementation
indicates that there is no difference in the systemic elimination of MMC, which is
chiefly occurred in the liver, between the two groups. However, elongation of the
half-life in the embolization group suggests that the ischemia of the liver might be
exerting some influence on the elimination of MMC from the liver blood flow and
tissue.
Here, "no difference" should be noted. In this experiment, MMC was directly
injected into the hepatic artery, so intrinsic clearance (CL D/AUC) of MMC can
be calculated from the data of AUC in femoral vein. From the data shown in this
paper, intrinsic clearance of MMC with or without Gelfoam is considered to have
no difference. This means no increase of toxicity with sup-plementation of Gelfoam
in the normal liver tissue, and suggests advantageous result for chemoembolization
from the aspect of side effects.
It is well known that the arterial blood supply is dominant in hepatic tumors and
the pharmacokinetics of antitumor drugs in tumors are surmised to be different
from normal hepatocytes, which are also fed by the portal vein. In fact, experi-
ments concluded at our institution by infusing a mixture of doxorubicin and an
embolic material into the hepatic artery demonstrated a significant increase in the
doxorubicin concentration in tumor tissue compared to the normal liver tissue.
Therefore, in order to more accurately investigate the effect of chemoemboliza-
tion, further studies on the pharmacokinetics of MMC in tumor tissue are needed.
Lipiodol and degradable starch microspheres (DSM) are also used as an embolic
material. These substances have a smaller diameter than Gelfoam and many
authors have reported the clinical effectiveness of TAE using these materials.
Further studies on MMC with these embolic materials and using the method
established in this paper are looked forward to.
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